Navigation Links
KemPharm's KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
Date:8/26/2013

NORTH LIBERTY, Iowa, Aug. 26, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced positive results from one of several clinical and non-clinical studies that the company is performing in preparation for its New Drug Application (NDA) for KP201 (benzhydrocodone and acetaminophen), which the company anticipates filing in the second quarter of 2014.

In a two-stage, single and multiple-dose, oral pharmacokinetic (PK) study in 26 healthy volunteers, KP201 effectively released and achieved steady-state plasma concentrations of hydrocodone, its active metabolite hydromorphone and acetaminophen.  The data also confirmed that KP201 was metabolized completely and that no systemic prodrug exposure was observed in any subject at any time point during the study.  KP201 was also shown to be safe and well tolerated by the opioid-naive volunteers in the study.

Sven Guenther, Ph.D., Vice President of Research at KemPharm, commented, "The results of this study confirm two key benefits of KP201 and of our novel prodrug approach to abuse deterrence: 1) single and multiple doses of KP201 tablets release hydrocodone effectively only upon oral administration, and 2) the prodrug itself is metabolized completely and does not reach the systemic circulation, even at the maximum daily dose.  In the coming months, we anticipate reporting additional bioavailability and bioequivalence data that we expect will affirm the unique physicochemical and pharmacological attributes of KP201."

Travis C. Mickle, Ph.D., President and CEO of KemPharm, added, "This data set is an important milestone for KemPharm as it marks one of several clinical and non-clinical studies of KP201 that we expect to complete in preparation for the filing of an NDA in the second quarter of 2014.  As the safety, tolerability and PK performance of KP201 is further established, we believe the prodrug has the potential to fulfill a significant therapeutic and market need as a first-in-class opioid-based prodrug that possesses the ability to reduce abuse potential and opioid-induced constipation."

About KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle

319-665-2575

info@kempharm.com

 

 

Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020

jrando@tiberend.com

jdrumm@tiberend.com


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
2. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
3. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
4. Sectra Demonstrates Radiation Dose Monitoring System at AHRA and AAPM Meetings
5. New Data From Partners Center For Connected Health Demonstrates Wireless Mobile Technology Improves Patient Engagement, Outcomes
6. New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR
7. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
8. Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
9. New Cardiac Electrical Biomarker Featured In Johns Hopkins Abstract Demonstrates Strong Correlation To High Sensitivity Troponin To Rule Out Acute Myocardial Ischemic Injury
10. MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013 CeBIT
11. West Health Institute demonstrates research advances in medical device interoperability to lower the cost of health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, announced ... acquire a majority ownership interest in Dental Cremer S.A., ... Brazil . --> ... is the dental distribution business of Cremer S.A. With ...
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... in the United States District Court for the District of ... (the "Class") consisting of all persons or entities who purchased ... (NASDAQ: INSY ) from March 3, 2015 through January ... certain of its officers with violations of the Securities Exchange ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University ... Allen have signed a joint enrollment and degree completion agreement. The agreement, ... and baccalaureate degrees at FHU|Dickson. , The agreement allows students to be ...
(Date:2/5/2016)... Illinois (PRWEB) , ... February 05, 2016 , ... ... and independent PROSHRED franchises from across the country gathered at the La Valencia ... recognize top performers. PROSHRED Chicago was named the year’s most outstanding franchise, ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled ... provide the most effective tattoo removal today, Dr. Bentkover is the only doctor in ... Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) as ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Health and ... more relevant to individuals in the event they are experiencing an illness. Migraines are ... Those Americans that are afflicted with migraines would not wish the pain on their ...
Breaking Medicine News(10 mins):